
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6359821/publications.pdf Version: 2024-02-01



RONALD CO

#	Article	IF	CITATIONS
1	Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet, The, 2008, 371, 395-403.	13.7	784
2	Review of the Comparative Pharmacology and Clinical Activity of Cisplatin and Carboplatin. Journal of Clinical Oncology, 1999, 17, 409-409.	1.6	603
3	MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. Blood, 2013, 121, 4021-4031.	1.4	596
4	Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases. JAMA - Journal of the American Medical Association, 2017, 317, 48.	7.4	253
5	Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death. Blood, 2017, 129, 2111-2119.	1.4	249
6	Representation of Minorities and Women in Oncology Clinical Trials: Review of the Past 14 Years. Journal of Oncology Practice, 2018, 14, e1-e10.	2.5	245
7	Nonâ€< scp>Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the <scp>US</scp> : A longitudinal analysis of the <scp>N</scp> ational <scp>C</scp> ancer <scp>D</scp> ata <scp>B</scp> ase from 1998 to 2011. American Journal of Hematology, 2015, 90, 790-795.	4.1	221
8	CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Blood, 2013, 121, 2715-2724.	1.4	206
9	Immunophenotypic and molecular features, clinical outcomes, treatments, and prognostic factors associated with subcutaneous panniculitisâ€like Tâ€cell lymphoma. Cancer, 2004, 101, 1404-1413.	4.1	192
10	Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era. Blood, 2020, 135, 1929-1945.	1.4	191
11	Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. Blood Cancer Journal, 2018, 8, 59.	6.2	171
12	Radiofrequency Ablation Versus Stereotactic Body Radiotherapy for Localized Hepatocellular Carcinoma in Nonsurgically Managed Patients: Analysis of the National Cancer Database. Journal of Clinical Oncology, 2018, 36, 600-608.	1.6	160
13	Improved quality of life for romiplostimâ€treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placeboâ€controlled trials. British Journal of Haematology, 2009, 144, 409-415.	2.5	150
14	Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study. Haematologica, 2013, 98, 255-263.	3.5	142
15	How I treat autoimmune hemolytic anemia. Blood, 2017, 129, 2971-2979.	1.4	134
16	Level of Scientific Evidence Underlying Recommendations Arising From the National Comprehensive Cancer Network Clinical Practice Guidelines. Journal of Clinical Oncology, 2011, 29, 186-191.	1.6	129
17	Deep Venous Thrombosis of the Arm After Intravenous Immunoglobulin Infusion: Case Report and Literature Review of Intravenous Immunoglobulin-Related Thrombotic Complications. Mayo Clinic Proceedings, 2000, 75, 83-85.	3.0	125
18	Primary Testicular Diffuse Large B-Cell Lymphoma: A Population-Based Study on the Incidence, Natural History, and Survival Comparison With Primary Nodal Counterpart Before and After the Introduction of Rituximab. Journal of Clinical Oncology, 2009, 27, 5227-5232.	1.6	124

#	Article	IF	CITATIONS
19	The Mayo Clinic Histiocytosis Working Group Consensus Statement for the Diagnosis and Evaluation of Adult Patients With Histiocytic Neoplasms: Erdheim-Chester Disease, Langerhans Cell Histiocytosis, and Rosai-Dorfman Disease. Mayo Clinic Proceedings, 2019, 94, 2054-2071.	3.0	116
20	Trends in survival of patients with primary plasma cell leukemia: a population-based analysis. Blood, 2014, 124, 907-912.	1.4	111
21	Diagnosis and Management of Waldenström Macroglobulinemia. JAMA Oncology, 2017, 3, 1257.	7.1	110
22	Treatment of Immunoglobulin Light Chain Amyloidosis. Mayo Clinic Proceedings, 2015, 90, 1054-1081.	3.0	106
23	Clinicopathological features, treatment approaches, and outcomes in Rosai-Dorfman disease. Haematologica, 2020, 105, 348-357.	3.5	105
24	Acquired pure red cell aplasia associated with lymphoproliferative disease of granular T lymphocytes. Blood, 2001, 98, 483-485.	1.4	99
25	Racial/ethnic differences in clinical trial enrollment, refusal rates, ineligibility, and reasons for decline among patients at sites in the National Cancer Institute's Community Cancer Centers Program. Cancer, 2014, 120, 877-884.	4.1	97
26	How I manage monoclonal gammopathy of undetermined significance. Blood, 2018, 131, 163-173.	1.4	88
27	Outcome of Whole Exome Sequencing for Diagnostic Odyssey Cases of an Individualized Medicine Clinic. Mayo Clinic Proceedings, 2016, 91, 297-307.	3.0	83
28	Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement. Bone Marrow Transplantation, 2019, 54, 353-367.	2.4	81
29	Thrombotic microangiopathy associated with monoclonal gammopathy. Kidney International, 2017, 91, 691-698.	5.2	78
30	Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosis. American Journal of Hematology, 2015, 90, 181-186.	4.1	76
31	Clinical presentation and outcomes of patients with type 1 monoclonal cryoglobulinemia. American Journal of Hematology, 2017, 92, 668-673.	4.1	75
32	Histiocytic sarcoma: a population-based analysis of incidence, demographic disparities, and long-term outcomes. Blood, 2018, 131, 265-268.	1.4	73
33	The association between platelet autoantibody specificity and response to intravenous immunoglobulin G in the treatment of patients with immune thrombocytopenia. Haematologica, 2007, 92, 283-284.	3.5	72
34	Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis. Mayo Clinic Proceedings, 2017, 92, 908-917.	3.0	72
35	Nâ€ŧerminal fragment of the typeâ€B natriuretic peptide (NTâ€proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma. American Journal of Hematology, 2016, 91, 1129-1134.	4.1	71
36	The impact of postpartum hemorrhage on hospital length ofÂstay and inpatient mortality: a National Inpatient Sample–based analysis. American Journal of Obstetrics and Gynecology, 2017, 217, 344.e1-344.e6.	1.3	71

#	Article	IF	CITATIONS
37	Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia. Annals of Hematology, 2018, 97, 1417-1425.	1.8	71
38	Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria. Leukemia, 2018, 32, 2240-2249.	7.2	64
39	Revised diagnostic criteria for plasma cell leukemia: results of a Mayo Clinic study with comparison of outcomes to multiple myeloma. Blood Cancer Journal, 2018, 8, 116.	6.2	64
40	Neoadjuvant vs. adjuvant chemotherapy for cholangiocarcinoma: AÂpropensity score matched analysis. European Journal of Surgical Oncology, 2019, 45, 1432-1438.	1.0	63
41	International expert consensus recommendations for the diagnosis and treatment of Langerhans cell histiocytosis in adults. Blood, 2022, 139, 2601-2621.	1.4	63
42	A Modern Primer on Light Chain Amyloidosis in 592 Patients With Mass Spectrometry–Verified Typing. Mayo Clinic Proceedings, 2019, 94, 472-483.	3.0	59
43	Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response. Blood Cancer Journal, 2020, 10, 82.	6.2	59
44	Association Between Treatment Facility Volume and Mortality of Patients With Multiple Myeloma. Journal of Clinical Oncology, 2017, 35, 598-604.	1.6	58
45	Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities. Blood Advances, 2020, 4, 3509-3519.	5.2	58
46	Longâ€ŧerm outcome of patients with POEMS syndrome: An update of the Mayo Clinic experience. American Journal of Hematology, 2016, 91, 585-589.	4.1	57
47	<i>MYD88</i> mutation status does not impact overall survival in Waldenström macroglobulinemia. American Journal of Hematology, 2018, 93, 187-194.	4.1	57
48	Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma. Blood Cancer Journal, 2016, 6, e454-e454.	6.2	56
49	Use of autologous hematopoietic cell transplantation as initial therapy in multiple myeloma and the impact of socioâ€geoâ€demographic factors in the era of novel agents. American Journal of Hematology, 2014, 89, 825-830.	4.1	55
50	Thrombotic Microangiopathy Care Pathway: A Consensus Statement for the Mayo Clinic Complement Alternative Pathway-Thrombotic Microangiopathy (CAP-TMA) Disease-Oriented Group. Mayo Clinic Proceedings, 2016, 91, 1189-1211.	3.0	55
51	Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma. Blood, 2017, 130, 1198-1204.	1.4	54
52	Determining the Clinical Significance of Monoclonal Gammopathy of Undetermined Significance: A SEER–Medicare Population Analysis. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 177-186.e4.	0.4	52
53	Rosai-Dorfman Disease Displays a Unique Monocyte-Macrophage Phenotype Characterized by Expression of OCT2. American Journal of Surgical Pathology, 2021, 45, 35-44.	3.7	52
54	Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib. Blood, 2016, 128, 2415-2422.	1.4	51

#	Article	IF	CITATIONS
55	Independent Prognostic Value of Stroke Volume Index in Patients With Immunoglobulin Light Chain Amyloidosis. Circulation: Cardiovascular Imaging, 2018, 11, e006588.	2.6	51
56	The prognostic value of multiparametric flow cytometry in AL amyloidosis at diagnosis and at the end of first-line treatment. Blood, 2017, 129, 82-87.	1.4	50
57	Efficacy of VDT PACEâ€like regimens in treatment of relapsed/refractory multiple myeloma. American Journal of Hematology, 2018, 93, 179-186.	4.1	49
58	Rectal Administration of Iodide and Propylthiouracil in the Treatment of Thyroid Storm. Thyroid, 1995, 5, 403-405.	4.5	47
59	Clinical and Radiologic Responses to Cladribine for the Treatment of Erdheim-Chester Disease. JAMA Oncology, 2017, 3, 1253.	7.1	47
60	¹⁸ F-FDG PET/CT in Erdheim–Chester Disease: Imaging Findings and Potential BRAF Mutation Biomarker. Journal of Nuclear Medicine, 2018, 59, 774-779.	5.0	46
61	Induction therapy preâ€autologous stem cell transplantation in immunoglobulin light chain amyloidosis: a retrospective evaluation. American Journal of Hematology, 2016, 91, 984-988.	4.1	45
62	Overuse of organ biopsies in immunoglobulin light chain amyloidosis (AL): the consequence of failure of early recognition. Annals of Medicine, 2017, 49, 545-551.	3.8	45
63	Aplastic anemia and pure red cell aplasia associated with large granular lymphocyte leukemia. Seminars in Hematology, 2003, 40, 196-200.	3.4	44
64	Lymphoproliferative disease of granular T lymphocytes presenting as aplastic anemia. Blood, 2000, 96, 3644-3646.	1.4	43
65	Systemic Immunoglobulin Light Chain Amyloidosis–Associated Myopathy: Presentation, Diagnostic Pitfalls, and Outcome. Mayo Clinic Proceedings, 2016, 91, 1354-1361.	3.0	43
66	Neuroradiologic manifestations of Erdheim-Chester disease. Neurology: Clinical Practice, 2018, 8, 15-20.	1.6	43
67	Adult disseminated Langerhans cell histiocytosis: incidence, racial disparities and longâ€ŧerm outcomes. British Journal of Haematology, 2018, 182, 579-581.	2.5	43
68	Use of the National Cancer Institute Community Cancer Centers Program Screening and Accrual Log to Address Cancer Clinical Trial Accrual. Journal of Oncology Practice, 2014, 10, e73-e80.	2.5	42
69	Single nucleotide variation in the TP53 3′ untranslated region in diffuse large B-cell lymphoma treated with rituximab-CHOP: a report from the International DLBCL Rituximab-CHOP Consortium Program. Blood, 2013, 121, 4529-4540.	1.4	41
70	In-Hospital Outcomes of Tumor Lysis Syndrome: A Population-Based Study Using the National Inpatient Sample. Oncologist, 2017, 22, 1506-1509.	3.7	41
71	Betaâ€blockers improve survival outcomes in patients with multiple myeloma: a retrospective evaluation. American Journal of Hematology, 2017, 92, 50-55.	4.1	41
72	Impact of acquired del(17p) in multiple myeloma. Blood Advances, 2019, 3, 1930-1938.	5.2	41

#	Article	lF	CITATIONS
73	lbrutinib monotherapy outside of clinical trial setting in Waldenström macroglobulinaemia: practice patterns, toxicities and outcomes. British Journal of Haematology, 2020, 188, 394-403.	2.5	41
74	Prevalence of and Recovery From Anemia Following Hospitalization for Critical Illness Among Adults. JAMA Network Open, 2020, 3, e2017843.	5.9	41
75	Tenâ€year survivors in AL amyloidosis: characteristics and treatment pattern. British Journal of Haematology, 2019, 187, 588-594.	2.5	40
76	Outcomes of primary refractory multiple myeloma and the impact of novel therapies. American Journal of Hematology, 2015, 90, 981-985.	4.1	38
77	Myelomatous Involvement of the Central Nervous System. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, 644-654.	0.4	38
78	Natural history of multiple myeloma with de novo del(17p). Blood Cancer Journal, 2019, 9, 32.	6.2	38
79	Idiopathic cyclic thrombocytopenia. Blood Reviews, 2005, 19, 53-59.	5.7	37
80	Representation of Minorities and Elderly Patients in Multiple Myeloma Clinical Trials. Oncologist, 2018, 23, 1076-1078.	3.7	37
81	Enhancing the Râ€ISS classification of newly diagnosed multiple myeloma by quantifying circulating clonal plasma cells. American Journal of Hematology, 2020, 95, 310-315.	4.1	37
82	Optimizing deep response assessment for AL amyloidosis using involved free light chain level at end of therapy: failure of the serum free light chain ratio. Leukemia, 2019, 33, 527-531.	7.2	36
83	Venetoclax for the treatment of translocation (11;14) AL amyloidosis. Blood Cancer Journal, 2020, 10, 55.	6.2	36
84	Approach to pancytopenia: Diagnostic algorithm for clinical hematologists. Blood Reviews, 2018, 32, 361-367.	5.7	35
85	Characterization of Comorbidities Limiting the Recruitment of Patients in Early Phase Clinical Trials. Oncologist, 2019, 24, 96-102.	3.7	35
86	Impact of minimal residual negativity using next generation flow cytometry on outcomes in light chain amyloidosis. American Journal of Hematology, 2020, 95, 497-502.	4.1	35
87	Atypical hemolytic uremic syndrome: Review of clinical presentation, diagnosis and management. Journal of Immunological Methods, 2018, 461, 15-22.	1.4	34
88	Erdheim-Chester disease with concomitant Rosai-Dorfman like lesions: a distinct entity mainly driven by <i>MAP2K1</i> . Haematologica, 2020, 105, e5-e8.	3.5	34
89	Autoimmune Hemolytic Anemia in Children. Journal of Pediatric Hematology/Oncology, 2016, 38, e120-e124.	0.6	33
90	Impact of MYD88 ^{L265P} mutation status on histological transformation of Waldenström Macroglobulinemia. American Journal of Hematology, 2020, 95, 274-281.	4.1	33

#	Article	IF	CITATIONS
91	Immunoglobulin light chain amyloidosis is diagnosed late in patients with preexisting plasma cell dyscrasias. American Journal of Hematology, 2014, 89, 1051-1054.	4.1	32
92	Implications of MYC Rearrangements in Newly Diagnosed Multiple Myeloma. Clinical Cancer Research, 2020, 26, 6581-6588.	7.0	32
93	Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 Update. Mayo Clinic Proceedings, 2021, 96, 1546-1577.	3.0	32
94	Acetyl-l-carnitine (ALCAR) for the prevention of chemotherapy-induced peripheral neuropathy in patients with relapsed or refractory multiple myeloma treated with bortezomib, doxorubicin and low-dose dexamethasone: a study from the Wisconsin Oncology Network. Cancer Chemotherapy and Pharmacology, 2014, 74, 875-882.	2.3	31
95	Soluble suppression of tumorigenicity 2 (s <scp>ST</scp> 2), but not galactinâ€3, adds to prognostication in patients with systemic <scp>AL</scp> amyloidosis independent of <scp>NT</scp> â€pro <scp>BNP</scp> and troponin <scp>T</scp> . American Journal of Hematology, 2015, 90, 524-528.	4.1	31
96	Clinical characteristics and outcomes in biclonal gammopathies. American Journal of Hematology, 2016, 91, 473-475.	4.1	30
97	Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival. Leukemia, 2017, 31, 92-99.	7.2	30
98	A simple additive staging system for newly diagnosed multiple myeloma. Blood Cancer Journal, 2022, 12, 21.	6.2	30
99	Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcome. Blood Cancer Journal, 2018, 8, 125.	6.2	29
100	Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis. Leukemia, 2020, 34, 1135-1143.	7.2	29
101	Gender Differences in Faculty Rank and Leadership Positions Among Hematologists and Oncologists in the United States. JCO Oncology Practice, 2020, 16, e507-e516.	2.9	29
102	Prognostic significance of interphase FISH in monoclonal gammopathy of undetermined significance. Leukemia, 2018, 32, 1811-1815.	7.2	28
103	Outcomes with early response to first-line treatment in patients with newly diagnosed multiple myeloma. Blood Advances, 2019, 3, 744-750.	5.2	28
104	Primary systemic amyloidosis in patients with Waldenström macroglobulinemia. Leukemia, 2019, 33, 790-794.	7.2	28
105	"Real-life―data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma—the Mayo Clinic experience. Blood Cancer Journal, 2021, 11, 196.	6.2	28
106	Bortezomib-based consolidation or maintenance therapy for multiple myeloma: a meta-analysis. Blood Cancer Journal, 2020, 10, 33.	6.2	26
107	Blood mass spectrometry detects residual disease better than standard techniques in light-chain amyloidosis. Blood Cancer Journal, 2020, 10, 20.	6.2	26
108	Histiocytic Neoplasms, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 1277-1303.	4.9	26

#	Article	IF	CITATIONS
109	Langerhans Cell Histiocytosis and Other Histiocytic Diseases of the Lung. Clinics in Chest Medicine, 2016, 37, 421-430.	2.1	25
110	The impact of dialysis on the survival of patients with immunoglobulin light chain (AL) amyloidosis undergoing autologous stem cell transplantation. Nephrology Dialysis Transplantation, 2016, 31, 1284-1289.	0.7	25
111	Dexamethasone, rituximab and cyclophosphamide for relapsedÂand/or refractory and treatmentâ€naÃ⁻ve patients with Waldenstrom macroglobulinemia. British Journal of Haematology, 2017, 179, 98-105.	2.5	25
112	Efficacy of daratumumabâ€based therapies in patients with relapsed, refractory multiple myeloma treated outside of clinical trials. American Journal of Hematology, 2017, 92, 1146-1155.	4.1	25
113	Survival impact of achieving minimal residual negativity by multi-parametric flow cytometry in AL amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020, 27, 13-16.	3.0	25
114	Efficacy of BRAF-Inhibitor Therapy in <i>BRAF V600E</i> -Mutated Adult Langerhans Cell Histiocytosis. Oncologist, 2020, 25, 1001-1004.	3.7	25
115	MASS-FIX for the detection of monoclonal proteins and light chain N-glycosylation in routine clinical practice: a cross-sectional study of 6315 patients. Blood Cancer Journal, 2021, 11, 50.	6.2	25
116	Clinical Features and Treatment Outcomes of Patients With Necrobiotic Xanthogranuloma Associated With Monoclonal Gammopathies. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, 447-452.	0.4	24
117	Treatment patterns and outcome following initial relapse or refractory disease in patients with systemic light chain amyloidosis. American Journal of Hematology, 2017, 92, 549-554.	4.1	24
118	Efficacy of biological agents in the treatment of Erdheimâ€Chester disease. British Journal of Haematology, 2018, 183, 520-524.	2.5	24
119	Arterial involvement in Erdheim–Chester disease. Medicine (United States), 2018, 97, e13452.	1.0	24
120	Predictors of symptomatic hyperviscosity in Waldenström macroglobulinemia. American Journal of Hematology, 2018, 93, 1384-1393.	4.1	24
121	Cardiac prosthesesâ€related hemolytic anemia. Clinical Cardiology, 2019, 42, 692-700.	1.8	24
122	Acute myelogenous leukemia in an adult with thrombocytopenia with absent radii syndrome. European Journal of Haematology, 2003, 70, 246-248.	2.2	23
123	Cancer in the oldest old in the United States: Current statistics and projections. Journal of Geriatric Oncology, 2012, 3, 299-306.	1.0	23
124	Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma. Blood Advances, 2018, 2, 3149-3154.	5.2	23
125	Tumor mutational burden and other predictive immunotherapy markers in histiocytic neoplasms. Blood, 2019, 133, 1607-1610.	1.4	23
126	Publication Outcomes of Phase II Oncology Clinical Trials. American Journal of Clinical Oncology: Cancer Clinical Trials, 2009, 32, 253-257.	1.3	22

#	Article	IF	CITATIONS
127	Influence of the treatment facility volume on the survival of patients with nonâ€Hodgkin lymphoma. Cancer, 2016, 122, 2552-2559.	4.1	22
128	Association between hospital volume and mortality of patients with metastatic non-small cell lung cancer, 2018, 122, 214-219.	2.0	22
129	Comparative analysis of staging systems in AL amyloidosis. Leukemia, 2019, 33, 811-814.	7.2	22
130	Delineation of the timing of second-line therapy post–autologous stem cell transplant in patients with AL amyloidosis. Blood, 2017, 130, 1578-1584.	1.4	21
131	Implications of detecting serum monoclonal protein by MASSâ€fix following stem cell transplantation in multiple myeloma. British Journal of Haematology, 2021, 193, 380-385.	2.5	21
132	Singleâ€agent cladribine as an effective frontâ€line therapy for adults with Langerhans cell histiocytosis. American Journal of Hematology, 2021, 96, E146-E150.	4.1	21
133	Venetoclax for the treatment of multiple myeloma: Outcomes outside of clinical trials. American Journal of Hematology, 2021, 96, 1131-1136.	4.1	21
134	Angiogenesis in rat aortic rings stimulated by very low concentrations of serum and plasma. Angiogenesis, 2003, 6, 25-29.	7.2	20
135	Treatment approaches and outcomes in plasmacytomas: analysis using a national dataset. Leukemia, 2018, 32, 1414-1420.	7.2	20
136	Relapse after complete response in newly diagnosed multiple myeloma: implications of duration of response and patterns of relapse. Leukemia, 2019, 33, 730-738.	7.2	20
137	Prevalence and survival of smouldering Waldenström macroglobulinaemia in the United States. British Journal of Haematology, 2019, 184, 1014-1017.	2.5	20
138	Metaphase cytogenetics and plasma cell proliferation index for risk stratification in newly diagnosed multiple myeloma. Blood Advances, 2020, 4, 2236-2244.	5.2	20
139	Commentary: Race and Ethnicity in Biomedical Research – Classifications, Challenges, and Future Directions. Ethnicity and Disease, 2018, 28, 561-564.	2.3	19
140	Utility and prognostic value of ¹⁸ Fâ€FDG positron emission tomographyâ€computed tomography scans in patients with newly diagnosed multiple myeloma. American Journal of Hematology, 2018, 93, 1518-1523.	4.1	19
141	Influence of Sociodemographic Factors on Treatment Decisions in Non–Small-Cell Lung Cancer. Clinical Lung Cancer, 2020, 21, e115-e129.	2.6	19
142	Characteristics of late transplantâ€associated thrombotic microangiopathy in patients who underwent allogeneic hematopoietic stem cell transplantation. American Journal of Hematology, 2020, 95, 1170-1179.	4.1	19
143	Spectrum of hematological malignancies, clonal evolution and outcomes in 144 Mayo Clinic patients with germline predisposition syndromes. American Journal of Hematology, 2021, 96, 1450-1460.	4.1	19
144	Long-Term Follow up of Patients with Cold Agglutinin Disease Blood, 2005, 106, 3710-3710.	1.4	19

#	Article	IF	CITATIONS
145	Utility of Routine Left Ventricular Ejection Fraction Measurement Before Anthracycline-Based Chemotherapy in Patients With Diffuse Large B-Cell Lymphoma. Journal of Oncology Practice, 2012, 8, 336-340.	2.5	18
146	Predictors of early response to initial therapy in patients with newly diagnosed symptomatic multiple myeloma. American Journal of Hematology, 2015, 90, 888-891.	4.1	18
147	21-Gene recurrence score decreases receipt of chemotherapy in ER+ early-stage breast cancer: an analysis of the NCDB 2010–2013. Breast Cancer Research and Treatment, 2016, 159, 315-326.	2.5	18
148	Sex-based disparities in venous thromboembolism outcomes: A National Inpatient Sample (NIS)-based analysis. Vascular Medicine, 2017, 22, 121-127.	1.5	18
149	Peripheral blood biomarkers of early immune reconstitution in newly diagnosed multiple myeloma. American Journal of Hematology, 2019, 94, 306-311.	4.1	18
150	Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma. Blood Cancer Journal, 2018, 8, 70.	6.2	18
151	Association between anemia and hematological indices with mortality among cardiac intensive care unit patients. Clinical Research in Cardiology, 2020, 109, 616-627.	3.3	18
152	Long-term outcomes of IMiD-based trials in patients with immunoglobulin light-chain amyloidosis: a pooled analysis. Blood Cancer Journal, 2020, 10, 4.	6.2	18
153	Langerhans cell histiocytosis with lung involvement in isolation and multisystem disease: Staging, natural history, and comparative survival. American Journal of Hematology, 2021, 96, 1604-1610.	4.1	18
154	Incidence, clinical findings, and survival of hepatosplenic <scp>T</scp> ell lymphoma in the <scp>U</scp> nited <scp>S</scp> tates. American Journal of Hematology, 2017, 92, E99-E101.	4.1	17
155	Diagnostic Utility of Complement Serology for Atypical Hemolytic Uremic Syndrome. Mayo Clinic Proceedings, 2018, 93, 1351-1362.	3.0	17
156	Refining amyloid complete hematological response: Quantitative serum free light chains superior to ratio. American Journal of Hematology, 2020, 95, 1280-1287.	4.1	17
157	Clinical outcomes of adults with hemophagocytic lymphohistiocytosis treated with the HLH-04 protocol: a retrospective analysis. Leukemia and Lymphoma, 2020, 61, 1592-1600.	1.3	17
158	Hematology patient reported symptom screen to assess quality of life for AL amyloidosis. American Journal of Hematology, 2017, 92, 435-440.	4.1	16
159	Clinical Characteristics and Outcomes of Patients With Primary Plasma Cell Leukemia in the Era of Novel Agent Therapy. Mayo Clinic Proceedings, 2021, 96, 677-687.	3.0	16
160	Institutional Review of Compliance With NCCN Guidelines for Breast Cancer: Lessons Learned From Real-Time Multidimensional Synoptic Reporting. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 177-183.	4.9	15
161	Elevation of serum lactate dehydrogenase in <scp>AL</scp> amyloidosis reflects tissue damage and is an adverse prognostic marker in patients not eligible for stem cell transplantation. British Journal of Haematology, 2017, 178, 888-895.	2.5	15
162	Prognostic value of minimal residual disease and polyclonal plasma cells in myeloma patients achieving a complete response to therapy. American Journal of Hematology, 2019, 94, 751-756.	4.1	15

#	Article	IF	CITATIONS
163	Revisiting complete response in light chain amyloidosis. Leukemia, 2020, 34, 1472-1475.	7.2	15
164	Glycosylation of immunoglobulin light chains is highly prevalent in cold agglutinin disease. American Journal of Hematology, 2020, 95, E222-E225.	4.1	15
165	Increased Bone Marrow Plasma-Cell Percentage Predicts Outcomes in Newly Diagnosed Multiple Myeloma Patients. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 596-601.	0.4	15
166	Thrombocytopenia after Iron Dextran Administration in a Patient with Severe Iron Deficiency Anemia. Annals of Internal Medicine, 2000, 132, 925.	3.9	15
167	Clinical Presentation and Outcome of Patients with Myeloid Differentiation Factor 88 Gene (MYD88) Wild-Type Waldenstrom Macroglobulinemia. Blood, 2016, 128, 2960-2960.	1.4	15
168	Time to plateau as a predictor of survival in newly diagnosed multiple myeloma. American Journal of Hematology, 2018, 93, 889-894.	4.1	14
169	Biosimilar Filgrastim Uptake And Costs Among Commercially Insured, Medicare Advantage. Health Affairs, 2019, 38, 1887-1892.	5.2	14
170	Hematopoietic score predicts outcomes in newly diagnosed multiple myeloma patients. American Journal of Hematology, 2020, 95, 4-9.	4.1	14
171	The significance of genetic mutations and their prognostic impact on patients with incidental finding of isolated del(20q) in bone marrow without morphologic evidence of a myeloid neoplasm. Blood Cancer Journal, 2020, 10, 7.	6.2	14
172	BendamustineÂ+Ârituximab chemoimmunotherapy and maintenance lenalidomide in relapsed, refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma: AÂWisconsin Oncology Network Study. British Journal of Haematology, 2016, 173, 283-291.	2.5	13
173	Concomitant Erdheimâ€Chester disease and chronic myelomonocytic leukaemia: genomic insights into a common clonal origin. British Journal of Haematology, 2019, 187, e51-e54.	2.5	13
174	Characteristics of exceptional responders to autologous stem cell transplantation in multiple myeloma. Blood Cancer Journal, 2020, 10, 87.	6.2	13
175	Leukocytosis and Tobacco Use: An Observational Study of Asymptomatic Leukocytosis. American Journal of Medicine, 2021, 134, e31-e35.	1.5	13
176	Outcomes with different administration schedules of bortezomib in bortezomib, lenalidomide and dexamethasone (<scp>VRd</scp>) as firstâ€ine therapy in multiple myeloma. American Journal of Hematology, 2021, 96, 330-337.	4.1	13
177	Prognostic impact of posttransplant FDG PET/CT scan in multiple myeloma. Blood Advances, 2021, 5, 2753-2759.	5.2	13
178	Financial Conflicts of Interest Among ASCO Annual Meeting Abstract Authors, Speakers, and Planners. Journal of the National Cancer Institute, 2007, 99, 1415-1416.	6.3	12
179	Predictors of survival, treatment patterns, and outcomes in histiocytic sarcoma. Leukemia and Lymphoma, 2019, 60, 553-555.	1.3	12
180	Outcome of Myelodysplastic Syndromes Over Time in the United States: A National Cancer Data Base Study From 2004-2013. Mayo Clinic Proceedings, 2019, 94, 1467-1474.	3.0	12

#	Article	IF	CITATIONS
181	Substratification of patients with newly diagnosed standardâ€risk multiple myeloma. British Journal of Haematology, 2019, 185, 254-260.	2.5	12
182	Impact of prior diagnosis of monoclonal gammopathy on outcomes in newly diagnosed multiple myeloma. Leukemia, 2019, 33, 1273-1277.	7.2	12
183	Utilizing multiparametric flow cytometry in the diagnosis of patients with primary plasma cell leukemia. American Journal of Hematology, 2020, 95, 637-642.	4.1	12
184	Bone marrow findings in Erdheim-Chester disease: increased prevalence of chronic myeloid neoplasms. Haematologica, 2020, 105, e84-e86.	3.5	12
185	Category of evidence and consensus underlying National Comprehensive Cancer Network guidelines: Is there evidence of progress?. International Journal of Cancer, 2021, 148, 429-436.	5.1	12
186	Coagulation Abnormalities in Light Chain Amyloidosis. Mayo Clinic Proceedings, 2021, 96, 377-387.	3.0	12
187	Assessment of fixedâ€duration therapies for treatmentâ€naÃ⁻ve <scp>Waldenström</scp> macroglobulinemia. American Journal of Hematology, 2021, 96, 945-953.	4.1	12
188	Disease outcomes and biomarkers of progression in smouldering Waldenström macroglobulinaemia. British Journal of Haematology, 2021, 195, 210-216.	2.5	12
189	Early-Phase Clinical Trials In The Community: Results From the National Cancer Institute Community Cancer Centers Program Early-Phase Working Group Baseline Assessment. Journal of Oncology Practice, 2013, 9, e55-e61.	2.5	11
190	Making the Case to Study the Volume-Outcome Relationship in Hematologic Cancers. Mayo Clinic Proceedings, 2015, 90, 1393-1399.	3.0	11
191	Pseudo-monoclonal gammopathy: a report of four cases. Haematologica, 2017, 102, e466-e469.	3.5	11
192	Impact of involved free light chain (FLC) levels in patients achieving normal FLC ratio after initial therapy in light chain amyloidosis (AL). American Journal of Hematology, 2018, 93, 17-22.	4.1	11
193	Rapid assessment of hyperdiploidy in plasma cell disorders using a novel multiâ€parametric flow cytometry method. American Journal of Hematology, 2019, 94, 424-430.	4.1	11
194	Financial conflicts of interest among National Comprehensive Cancer Network clinical practice guideline panelists in 2019. Cancer, 2020, 126, 3742-3749.	4.1	11
195	Natural history of amyloidosis isolated to fat and bone marrow aspirate. British Journal of Haematology, 2017, 179, 170-172.	2.5	10
196	Interpreting sulfhemoglobin and methemoglobin in patients with cyanosis: An overview of patients with Mâ€hemoglobin variants. International Journal of Laboratory Hematology, 2021, 43, 837-844.	1.3	10
197	Phase 2 Trial of Ixazomib, Lenalidomide, Dexamethasone and Daratumumab in Patients with Newly Diagnosed Multiple Myeloma. Blood, 2018, 132, 304-304.	1.4	10
198	Contralateral testicular relapse after prophylactic radiation in a patient with primary testicular diffuse large Bâ€cell lymphoma. European Journal of Haematology, 2009, 83, 603-605.	2.2	9

#	Article	IF	CITATIONS
199	ECOG Phase II Trial of Graded-Dose Peginterferon α-2b in Patients with Metastatic Melanoma Overexpressing Basic Fibroblast Growth Factor (E2602). Clinical Cancer Research, 2013, 19, 6597-6604.	7.0	9
200	Clinical course of patients with incidental finding of 20q―in the bone marrow without a morphologic evidence of myeloid neoplasm. American Journal of Hematology, 2016, 91, 556-559.	4.1	9
201	Immunoparesis status in immunoglobulin light chain amyloidosis at diagnosis affects response and survival by regimen type. Haematologica, 2016, 101, 1102-1109.	3.5	9
202	Mixed-phenotype large granular lymphocytic leukemia: a rare subtype in the large granular lymphocytic leukemia spectrum. Human Pathology, 2018, 81, 96-104.	2.0	9
203	T cell/histiocyteâ€rich large B cell lymphoma: incidence, demographic disparities, and longâ€ŧerm outcomes. British Journal of Haematology, 2019, 185, 140-142.	2.5	9
204	Depth of organ response in AL amyloidosis is associated with improved survival: new proposed organ response criteria. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 101-102.	3.0	9
205	Incidence, Clinical Features, and Outcomes of Langerhans Cell Sarcoma in the United States. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 441-446.	0.4	9
206	Low-dose vemurafenib monotherapy in <i>BRAF^{V600E}</i> -mutated Erdheim-Chester disease. Leukemia and Lymphoma, 2020, 61, 2733-2737.	1.3	9
207	Monitoring Ravulizumab effect on complement assays. Journal of Immunological Methods, 2021, 490, 112944.	1.4	9
208	Prognostic restaging after treatment initiation in patients with AL amyloidosis. Blood Advances, 2021, 5, 1029-1036.	5.2	9
209	The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma: A Cross-analysis of a Population-based Registry and a Tertiary Care Center. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 451-460.e2.	0.4	9
210	Assessment of Psychological Distress in Patients Suffering from Hematological Disorders Blood, 2007, 110, 636-636.	1.4	9
211	Adult Langerhans cell histiocytosis: A contemporary single-institution series of 186 patients Journal of Clinical Oncology, 2019, 37, 7018-7018.	1.6	9
212	A populationâ€based study of outcomes in polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the United States from 2001 to 2015: Comparison with data from a Mayo Clinic single institutional series. American Journal of Hematology, 2021, 96, E464-E468.	4.1	9
213	Sustained, complete response to pexidartinib in a patient with <scp><i>CSF1R</i></scp> â€mutated Erdheim–Chester disease. American Journal of Hematology, 2022, 97, 293-302.	4.1	9
214	Transient monosomy 7 in a chronic myelogenous leukemia patient during nilotinib therapy: a case report. Clinical Case Reports (discontinued), 2016, 4, 282-286.	0.5	8
215	Treatment Patterns and Outcomes in Early-stage Hodgkin Lymphoma in the Elderly: A National Cancer Database Analysis. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 812-818.	0.4	8
216	Clinical and radiological responses to oral methotrexate alone or in combination with other agents in Erdheim-Chester disease. Blood Cancer Journal, 2017, 7, 647.	6.2	8

#	Article	IF	CITATIONS
217	Monoclonal Gammopathy of Undetermined Significance. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2017, 1, 161-169.	2.4	8
218	Prognostic significance of circulating plasma cells by multi-parametric flow cytometry in light chain amyloidosis. Leukemia, 2018, 32, 1421-1426.	7.2	8
219	Cytogenetic Features and Clinical Outcomes of Patients With Non-secretory Multiple Myeloma in the Era of Novel Agent Induction Therapy. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 53-56.	0.4	8
220	The role of bone marrow biopsy in patients with plasma cell disorders: should all patients with a monoclonal protein be biopsied?. Blood Cancer Journal, 2020, 10, 52.	6.2	8
221	A population-based study of chronic neutrophilic leukemia in the United States. Blood Cancer Journal, 2020, 10, 68.	6.2	8
222	Utility of serum free light chain ratio in response definition in patients with multiple myeloma. Blood Advances, 2020, 4, 322-326.	5.2	8
223	Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial design. Leukemia, 2021, 35, 3604-3607.	7.2	8
224	Comparison of the current renal staging, progression and response criteria to predict renal survival in <scp>AL</scp> amyloidosis using a <scp>Mayo</scp> cohort. American Journal of Hematology, 2021, 96, 446-454.	4.1	8
225	Randomized Phase 2 Trial of Two Different Doses of Ixazomib in Patients with Relapsed Multiple Myeloma Not Refractory to Bortezomib. Blood, 2015, 126, 3050-3050.	1.4	8
226	Waldenström Macroglobulinemia in the Very Elderly (≥75 years):Clinical Characteristics and Outcomes. Blood, 2020, 136, 44-45.	1.4	8
227	22-Year-Old Woman With Severe Microcytic Anemia. Mayo Clinic Proceedings, 2000, 75, 861-864.	3.0	7
228	Circulating endothelial cells in patients with chronic lymphocytic leukemia. Annals of Hematology, 2008, 87, 369-373.	1.8	7
229	Polyclonal Localized Light Chain Amyloidosis—AÂDistinct Entity?. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, 588-592.	0.4	7
230	Risk of progression of monoclonal gammopathy of undetermined significance into lymphoplasmacytic malignancies: determining demographic differences in the USA. Haematologica, 2018, 103, e123-e125.	3.5	7
231	Postsurgical thrombotic microangiopathy: Case series and review of the literature. European Journal of Haematology, 2019, 103, 307-318.	2.2	7
232	Comparison of different techniques to identify cardiac involvement in immunoglobulin light chain (AL) amyloidosis. Blood Advances, 2019, 3, 1226-1229.	5.2	7
233	Characteristics of longâ€ŧerm survivors with multiple myeloma: A National Cancer Data Base analysis. Cancer, 2019, 125, 3574-3581.	4.1	7
234	Prognostic restaging at the time of second-line therapy in patients with AL amyloidosis. Leukemia, 2019, 33, 1268-1272.	7.2	7

#	Article	IF	CITATIONS
235	Monoclonal Gammopathy of Undetermined Significance: Indications for Prediagnostic Testing, Subsequent Diagnoses, and Follow-up Practice at Mayo Clinic. Mayo Clinic Proceedings, 2020, 95, 944-954.	3.0	7
236	Determining Why and Which Clinicians Order Serum Protein Electrophoresis (SPEP), Subsequent Diagnoses Based On Indications, and Clinical Significance of Routine Follow-up: a Study of Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS) Blood, 2009, 114, 4883-4883.	1.4	7
237	Estimating the Risk of Progression of Monoclonal Gammopathy of Undetermined Significance into Lymphoplasmacytic Malignancies in the United States: Determining Demographic Differences Using a National Dataset. Blood, 2016, 128, 843-843.	1.4	7
238	Immune-mediated hemolytic anemia and thrombocytopenia in clonal B-cell disorders: a review. Clinical Advances in Hematology and Oncology, 2018, 16, 670-676.	0.3	7
239	Clinical and therapeutic implications of BRAF fusions in histiocytic disorders. Blood Cancer Journal, 2022, 12, .	6.2	7
240	Uncertainty and discordance in the staging and prognosis of diffuse large B ell lymphoma with isolated bilateral testicular involvement. American Journal of Hematology, 2009, 84, 762-763.	4.1	6
241	Enteropathyâ€associated Tâ€eell lymphoma in the US: higher incidence and poorer survival among Asians. British Journal of Haematology, 2016, 172, 990-992.	2.5	6
242	Estimating the annual volume of hematologic cancer cases per hematologist–oncologist in the United States: are we treating rare cancers too rarely?. Leukemia and Lymphoma, 2017, 58, 251-252.	1.3	6
243	Florid dermatopathic lymphadenopathy-A morphological mimic of Langerhans cell histiocytosis. Clinical Case Reports (discontinued), 2018, 6, 1637-1638.	0.5	6
244	A populationâ€based analysis of second primary malignancies in Tâ€cell neoplasms. British Journal of Haematology, 2019, 185, 338-342.	2.5	6
245	Etiologies of Extreme Thrombocytosis: A Contemporary Series. Mayo Clinic Proceedings, 2019, 94, 1542-1550.	3.0	6
246	A populationâ€based study of chronic eosinophilic <scp>leukemiaâ€not</scp> otherwise specified in the United States. American Journal of Hematology, 2020, 95, E257.	4.1	6
247	The differential diagnosis of basophilia in patients undergoing <scp>BCRâ€ABL</scp> testing. American Journal of Hematology, 2020, 95, E216-E217.	4.1	6
248	In Patients with Light-Chain (AL) Amyloidosis Myocardial Contraction Fraction (MCF) Is a Simple, but Powerful Prognostic Measure That Can be Calculated from a Standard Echocardiogram (ECHO). Blood, 2015, 126, 1774-1774.	1.4	6
249	Blastic Plasmacytoid Dendritic Cell Neoplasm. a Population-Based Analysis from the SEER and NCDB Databases. Blood, 2016, 128, 4789-4789.	1.4	6
250	NK/T cell lymphoma in the U.S: A population-based study using the National Cancer Database from 1998-2012 Journal of Clinical Oncology, 2016, 34, e19038-e19038.	1.6	6
251	Autoimmune Hemolytic Anemia: Diagnosis and Differential Diagnosis. Hematology/Oncology Clinics of North America, 2022, 36, 315-324.	2.2	6
252	Economic Cost and Sustainability of Oral Therapies in Precision Oncology. JCO Oncology Practice, 2022, 18, e1247-e1254.	2.9	6

#	Article	IF	CITATIONS
253	Pseudothrombocytopenia Associated With Multiple Myeloma. Mayo Clinic Proceedings, 2006, 81, 869.	3.0	5
254	Erdheim-Chester Disease. Mayo Clinic Proceedings, 2015, 90, 1310.	3.0	5
255	<i>Desiderosmia</i> (olfactory craving): A novel symptom associated with iron deficiency anemia. American Journal of Hematology, 2017, 92, E93-E94.	4.1	5
256	High prevalence of monoclonal gammopathy among patients with warm autoimmune hemolytic anemia. American Journal of Hematology, 2017, 92, E164-E166.	4.1	5
257	The prognostic significance of polyclonal bone marrow plasma cells in patients with relapsing multiple myeloma. American Journal of Hematology, 2017, 92, E507-E512.	4.1	5
258	Racial and ethnic disparities in the survival of adolescents and young adults with acute myeloid leukemia: a retrospective study using the US National Cancer Data Base. Leukemia and Lymphoma, 2017, 58, 1184-1189.	1.3	5
259	Association between facility volume and mortality of patients with classic Hodgkin lymphoma. Cancer, 2020, 126, 757-764.	4.1	5
260	Outcomes with early vs. deferred stem cell transplantation in light chain amyloidosis. Bone Marrow Transplantation, 2020, 55, 1297-1304.	2.4	5
261	A followâ€up on desiderosmia (olfactory craving), a novel symptom associated with iron deficiency anemia. American Journal of Hematology, 2017, 92, E546.	4.1	5
262	Clinical Presentation, Diagnosis, Treatment, and Outcome of Patients with Erdheim-Chester Disease: The Mayo Clinic Experience. Blood, 2014, 124, 1405-1405.	1.4	5
263	Presentation and Outcomes of Localized Amyloidosis: The Mayo Clinic Experience. Blood, 2015, 126, 4197-4197.	1.4	5
264	Efficacy of Carfilzomib (K), Pomalidomide (P), and Dexamethasone (d) in Heavily Pretreated Patients with Relapsed/ Refractory Multiple Myeloma (RRMM) in a Real World Setting. Blood, 2016, 128, 3337-3337.	1.4	5
265	Phase 1/2 trial of ixazomib, cyclophosphamide, and dexamethasone for newly diagnosed multiple myeloma (NDMM) Journal of Clinical Oncology, 2016, 34, 8002-8002.	1.6	5
266	Non-Hodgkin Lymphoma and American Indians/Alaska Natives: A SEER Population Study from 2000 to 2012. Blood, 2015, 126, 2110-2110.	1.4	5
267	Characteristics and risk factors for thrombosis in <scp>POEMS</scp> syndrome: A retrospective evaluation of 230 patients. American Journal of Hematology, 2022, 97, 209-215.	4.1	5
268	Impact of achieving a complete response to initial therapy of multiple myeloma and predictors of subsequent outcome. American Journal of Hematology, 2022, , .	4.1	5
269	Monoclonal gammopathy of undetermined significance: to screen or not to screen for multiple myeloma?. British Journal of Haematology, 2010, 149, 620-621.	2.5	4
270	Longâ€ŧerm disease control in patients with newly diagnosed multiple myeloma after suspension of lenalidomide therapy. American Journal of Hematology, 2014, 89, 302-305.	4.1	4

#	Article	IF	CITATIONS
271	Increased Multinucleated Megakaryocytes as an Isolated Finding in Bone Marrow. American Journal of Clinical Pathology, 2016, 146, 561-566.	0.7	4
272	Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 40-41.	3.0	4
273	Predictors of early treatment failure following initial therapy for systemic immunoglobulin light-chain amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 183-188.	3.0	4
274	Impact of prior melphalan exposure on stem cell collection in light chain amyloidosis. Bone Marrow Transplantation, 2018, 53, 326-333.	2.4	4
275	Predicting Time to First Treatment in Chronic Lymphocytic Leukemia Using Machine Learning Survival and Classification Methods. , 2018, , .		4
276	Development of thrombocytopenia during first-line treatment and survival outcomes in newly diagnosed multiple myeloma. Leukemia and Lymphoma, 2019, 60, 2960-2967.	1.3	4
277	Implications and outcomes of MRDâ€negative multiple myeloma patients with immunofixation positivity. American Journal of Hematology, 2020, 95, E60-E62.	4.1	4
278	Characterization and prognostic implication of delayed complete response in AL amyloidosis. European Journal of Haematology, 2021, 106, 354-361.	2.2	4
279	Immuneâ€related hematologic adverse events in the context of immune checkpoint inhibitor therapy. American Journal of Hematology, 2021, 96, E362-E367.	4.1	4
280	Phase 2 Trial of Ixazomib, Cyclophosphamide and Dexamethasone for Treatment of Previously Untreated Light Chain Amyloidosis. Blood, 2020, 136, 52-53.	1.4	4
281	Daratumumab, Ixazomib, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma. Blood, 2020, 136, 36-37.	1.4	4
282	Continued Improvement in Survival of Patients with Newly Diagnosed Multiple Myeloma (MM). Blood, 2020, 136, 30-31.	1.4	4
283	Bendamustine and Rituximab Versus Dexamethasone, Rituximab and Cyclophosphamide in Patients with Waldenstrom Macroglobulinemia (WM). Blood, 2016, 128, 2968-2968.	1.4	4
284	Clinical Associations, Treatment, and Outcomes of Renal-Limited Thrombotic Microangiopathy. Blood, 2018, 132, 4978-4978.	1.4	4
285	Risk of mortality and second malignancies in primary myelofibrosis before and after ruxolitinib approval. Leukemia Research, 2022, 112, 106770.	0.8	4
286	Catastrophic thromboembolism in a patient with acute lymphoblastic leukemia and hypereosinophilia. Haematologica, 2004, 89, EIM01.	3.5	4
287	Isolated anemia in patients with large granular lymphocytic leukemia (LGLL). Blood Cancer Journal, 2022, 12, 30.	6.2	4
288	EBV-positive peripheral T-cell lymphoma with extensive hemophagocytosis. Blood, 2014, 124, 3329-3329.	1.4	3

#	Article	IF	CITATIONS
289	Speed of Accrual Into Phase III Oncology Trials. American Journal of Clinical Oncology: Cancer Clinical Trials, 2015, 38, 575-582.	1.3	3
290	Exploring Big Data in Hematological Malignancies: Challenges and Opportunities. Current Hematologic Malignancy Reports, 2016, 11, 271-279.	2.3	3
291	Shiga Toxin as a Potential Trigger of CFHR1 Deletion-Associated Thrombotic Microangiopathy. American Journal of the Medical Sciences, 2018, 356, 492-498.	1.1	3
292	Serum free light chain measurements to reduce 24â€h urine monitoring in patients with multiple myeloma with measurable urine monoclonal protein. American Journal of Hematology, 2018, 93, 1207-1210.	4.1	3
293	Incidence and Mortality Outcomes in Allogeneic Transplant-Associated Thrombotic Microangiopathy. Biology of Blood and Marrow Transplantation, 2018, 24, S329-S330.	2.0	3
294	Utility of repeating bone marrow biopsy for confirmation of complete response in multiple myeloma. Blood Cancer Journal, 2020, 10, 95.	6.2	3
295	Use of beta blockers is associated with survival outcome of multiple myeloma patients treated with pomalidomide. European Journal of Haematology, 2021, 106, 433-436.	2.2	3
296	Treatment facility volume and patient outcomes in Waldenstrom macroglobulinemia. Leukemia and Lymphoma, 2021, 62, 308-315.	1.3	3
297	Level of Scientific Evidence Underlying the National Comprehensive Cancer Network Clinical Practice Guidelines for Hematologic Malignancies: Are We Moving Forward?. Oncology, 2021, 35, 390-396.	0.5	3
298	Second Stem Cell Transplantation for Relapsed Refractory Light Chain (AL) Amyloidosis. Transplantation and Cellular Therapy, 2021, 27, 589.e1-589.e6.	1.2	3
299	Sequential Comparison of Conventional Serum Immunofixation (IFE) to Mass Spectrometry-Based Assessment (MASS FIX) in Patients with Multiple Myeloma (MM). Blood, 2020, 136, 12-13.	1.4	3
300	The t(14;18)(q32;q21) Characterizes a Subset of Patients with Diffuse Large-B Cell Lymphoma of Germinal Center Origin with Poor Outcome: Report From the International DLBCL Rituximab-CHOP Consortium Program Study. Blood, 2011, 118, 949-949.	1.4	3
301	Angiogenic Blockade with Bevacizumab Does Not Increase Response to Lenalidomide and Low Dose Dexamethasone in Relapsed or Refractory Myeloma. Blood, 2012, 120, 5041-5041.	1.4	3
302	Radiation Therapy Significantly Improves Survival Of Patients With Diffuse Large B-Cell Lymphoma Associated With MYC Translocation: A Report From The International DLBCL Rituximab-CHOP Consortium Program. Blood, 2013, 122, 641-641.	1.4	3
303	Analysis of Serum Ferritin Levels As a Diagnostic Criteria for Hemophagocytic Lymphohistiocytosis (HLH) in Hospitalized Adult Patients. Blood, 2015, 126, 1014-1014.	1.4	3
304	Novel Genetic Variants in Complement-Mediated Thrombotic Microangiopath. Blood, 2015, 126, 1050-1050.	1.4	3
305	Impact of Bone Marrow Plasmacytosis on Outcome in Patients with AL Amyloidosis Following Autologous Stem Cell Transplant. Blood, 2015, 126, 3177-3177.	1.4	3
306	Bortezomib Versus Non-Bortezomib Based Treatment for Transplant Ineligible Patients with Light Chain Amyloidosis. Blood, 2016, 128, 3317-3317.	1.4	3

#	Article	IF	CITATIONS
307	Outcome of Myelodysplastic Syndromes over Time in the US: A National Cancer Data Base Study from 2004-2013. Blood, 2016, 128, 3604-3604.	1.4	3
308	Lymphoproliferative disease of granular T lymphocytes presenting as aplastic anemia. Blood, 2000, 96, 3644-3646.	1.4	3
309	Evolving changes in M-protein (M), quantitative involved immunoglobulin (Ig), and hemoglobin (Hb) to identify patients (pts) with ultra high-risk smoldering multiple myeloma (UHR-SMM) Journal of Clinical Oncology, 2016, 34, 8004-8004.	1.6	3
310	Low grade b-cell non-Hodgkin lymphomas (NHL) involving the central nervous system (CNS): An analysis from the National Cancer Database (NCDB) Journal of Clinical Oncology, 2017, 35, e13083-e13083.	1.6	3
311	Trends in Multiple Myeloma Incidence in the United States (US): Demographic and Geographic Considerations and Focus on Young Adults. Blood, 2018, 132, 5575-5575.	1.4	3
312	Mimics of Erdheim–Chester disease. British Journal of Haematology, 2021, , .	2.5	3
313	Impact of a Multidisciplinary Tumor Board on the Care of Patients with Histiocytic Disorders: The Histiocytosis Working Group experience. Oncologist, 2022, 27, 144-148.	3.7	3
314	Clinical features and outcomes of non-pulmonary unifocal adult Langerhans cell histiocytosis. Blood Cancer Journal, 2022, 12, .	6.2	3
315	Extent and Nature of Advertising in Leading Hematology-Oncology Journals. American Journal of Clinical Oncology: Cancer Clinical Trials, 2009, 32, 92-93.	1.3	2
316	Floral variant of follicular lymphoma. American Journal of Hematology, 2011, 86, 503-503.	4.1	2
317	Stage redistribution and survival among Medicare beneficiaries before and after the approval of positron emission tomography scan for non-Hodgkin lymphoma. Leukemia and Lymphoma, 2015, 56, 1544-1546.	1.3	2
318	Feeling run down: exercise-induced pancytopenia. British Journal of Haematology, 2017, 177, 672-672.	2.5	2
319	Reply to E.L. Pollom et al, N. Ohri et al, A. Fiorentino et al, D.R. Wahl et al, N. Kim et al, J. Boda-Heggemann et al, S. Rana et al, N. Sanuki et al, J.R. Olsen et al, G.L. Smith et al, and A. Shinde et al. Journal of Clinical Oncology, 2018, 36, 2567-2569.	1.6	2
320	Patterns and utility of vitamin B12 and folate testing in patients with isolated thrombocytopenia. Annals of Hematology, 2019, 98, 1993-1994.	1.8	2
321	Predictors of short-term survival in Waldenström Macroglobulinemia. Leukemia and Lymphoma, 2020, 61, 2975-2979.	1.3	2
322	Hapticophagia: Tactile chew cravings in iron deficiency anemia. American Journal of Hematology, 2020, 95, E107-E108.	4.1	2
323	Treatment and outcome of newly diagnosed multiple myeloma patients > 75 years old: a retrospective analysis. Leukemia and Lymphoma, 2021, 62, 3011-3018.	1.3	2
324	Acute Pancreatitis From Treatment With BRAF Inhibitors in Erdheim-Chester Disease. Pancreas, 2021, 50, e6-e8.	1.1	2

#	Article	IF	CITATIONS
325	Single-Agent Cladribine As an Effective Therapy for Adults with Langerhans Cell Histiocytosis. Blood, 2019, 134, 4189-4189.	1.4	2
326	Mortality of Patients with Multiple Myeloma after the Introduction of Novel Therapies in the United States. Blood, 2019, 134, 72-72.	1.4	2
327	Prognostic Implications of Serum Monoclonal Protein Positivity By Mass-Fix in Bone Marrow Minimal Residual Disease Negative (MRD-) Patients with Multiple Myeloma. Blood, 2019, 134, 4386-4386.	1.4	2
328	Phase 2 Trial of LDE225 and Lenalidomide Maintenance Post Autologous Stem Cell Transplant for Multiple Myeloma. Blood, 2019, 134, 1905-1905.	1.4	2
329	MASS-FIX for the Diagnosis of Plasma Cell Disorders: A Single Institution Experience of 4118 Patients. Blood, 2020, 136, 48-49.	1.4	2
330	Spectrum of Second Primary Malignancies in Pediatric and Adult Langerhans Cell Histiocytosis Cases. Blood, 2020, 136, 51-52.	1.4	2
331	Gene Expression Profiling of Multiple Patients with Cyclic Thrombocytopenia Reveals Consistent Profile Blood, 2005, 106, 219-219.	1.4	2
332	Prognostic Value of cMYC Gene Abnormalities in Diffuse Large B Cell Lymphoma Treated with Chemo-Immunotherapy. Blood, 2011, 118, 2664-2664.	1.4	2
333	Dexamethasone, Rituximab and Cyclophosphamide (DRC) As Salvage Therapy for Waldenstrom Macroglobulinemia. Blood, 2016, 128, 2972-2972.	1.4	2
334	OR32-1 Endocrine Manifestations of Erdheim-Chester Disease: The Mayo Clinic Experience. Journal of the Endocrine Society, 2019, 3, .	0.2	2
335	Clinical Features and Outcomes of Isolated Myeloid Sarcoma in the United States: Analysis Using a National Dataset. Blood, 2016, 128, 1618-1618.	1.4	2
336	Depth of Response in Waldenstrom Macroglobulinemia. Blood, 2018, 132, 4141-4141.	1.4	2
337	Plasma Cell Proliferative Index Is an Independent Predictor of Progression in Smoldering Multiple Myeloma. Blood, 2018, 132, 3160-3160.	1.4	2
338	Differential Effect of Rituximab on Relapse-Free Survival in De Novo and Relapsed Immune Thrombotic Thrombocytopenic Purpura in African-American and Caucasian Populations. Blood, 2019, 134, 90-90.	1.4	2
339	Clinical Features and Outcomes of Unifocal Adult Langerhans Cell Histiocytosis. Blood, 2019, 134, 1667-1667.	1.4	2
340	Molecular Alterations in Adult Histiocytic Neoplasms. Blood, 2019, 134, 2975-2975.	1.4	2
341	Low-Dose BRAF-Inhibitors in the Treatment of Histiocytic Disorders with the BRAF-V600E Mutation. Blood, 2019, 134, 5895-5895.	1.4	2
342	Use of Imaging During Staging and Surveillance of Localized Colon Cancer in a Large Insured Population. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 1355-1361.	4.9	2

#	Article	IF	CITATIONS
343	African American Race Is Associated with Decreased Relapse-Free Survival in Immune Thrombotic Thrombocytopenic Purpura. Blood, 2019, 134, 1066-1066.	1.4	2
344	Recommendations for Managing Adults With Histiocytic Neoplasms: New NCCN Guidelines. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 1355-1357.	4.9	2
345	Evidence of Classical Complement Pathway Involvement in a Subset of Patients with Warm Autoimmune Hemolytic Anemia. Blood, 2021, 138, 2001-2001.	1.4	2
346	Risk of Mortality and Leukemic Transformation in Primary Myelofibrosis before and after Ruxolitinib Approval. Blood, 2020, 136, 28-28.	1.4	2
347	Multicentric Castleman disease: A single center experience of treatment with a focus on autologous stem cell transplantation. American Journal of Hematology, 2022, , .	4.1	2
348	EDTA-dependent lymphocyte clumping. Haematologica, 2003, 88, EIM09.	3.5	2
349	USE OF PLEURAL FLUID PROSTATE SPECIFIC ANTIGEN IN THE DIAGNOSIS OF MALIGNANT EFFUSION FROM METASTATIC PROSTATE CANCER. Journal of Urology, 2000, 164, 459-459.	0.4	1
350	Poor access to clinical trials among newly diagnosed adult cancer patients in the community—1999—2004. Community Oncology, 2007, 4, 695-700.	0.2	1
351	Issues Behind Disclosure of Conflicts of Interest. JAMA - Journal of the American Medical Association, 2008, 300, 2120.	7.4	1
352	Mutational Profile and Prognostic Significance of TP53 in Diffuse Large B-cell Lymphoma Patients Treated with Rituximab-CHOP: A Report From an International DLBCL Rituximab-CHOP Consortium Program Study. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, S382.	0.4	1
353	Immunoparesis status in AL amyloidosis at diagnosis affects response and survival by regimen type. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 44-45.	3.0	1
354	Pompe Disease Could Mimic Exam Findings of Amyloidosis: Two Rare Diagnoses Bona Fide. Case Reports in Hematology, 2018, 2018, 1-4.	0.4	1
355	Venetoclax For The Treatment of Translocation AL Amyloidosis. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e332.	0.4	1
356	Changes in Frequency of Surveillance Imaging of Survivors of Diffuse Large B-Cell Lymphoma After the American Society of Hematology Choosing Wisely Recommendations. JCO Oncology Practice, 2021, 17, e490-e496.	2.9	1
357	Teaching Neurolmages: Brain and Skin Involvement in Erdheim-Chester Disease. Neurology, 2021, 96, e1590-e1592.	1.1	1
358	Conflicts of interest (COI) among the UpToDate oncology management authors Journal of Clinical Oncology, 2021, 39, e13573-e13573.	1.6	1
359	The economic cost and sustainability of the precision oncology promise Journal of Clinical Oncology, 2021, 39, 7-7.	1.6	1
360	Immune-Mediated Hematologic Complications of Checkpoint Inhibitors: A Review of the Literature. Blood, 2018, 132, 5883-5883.	1.4	1

#	Article	IF	CITATIONS
361	Changes in Imaging Surveillance of Diffuse Large B-Cell Lymphoma Survivors after Publication of the American Society of Hematology Choosing Wisely® Recommendations. Blood, 2018, 132, 618-618.	1.4	1
362	Glycosylation of Immunoglobulin Light Chains Is Highly Prevalent in Cold Agglutinin Disease. Blood, 2019, 134, 3510-3510.	1.4	1
363	Utilizing Multiparametric Flow Cytometry to Identify Patients with Primary Plasma Cell Leukemia at Diagnosis. Blood, 2019, 134, 4334-4334.	1.4	1
364	Immune-Related Hematologic Adverse Events in the Context of Checkpoint Inhibitors. Blood, 2020, 136, 31-32.	1.4	1
365	Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon Beta, in Patients with Relapsed or Refractory Multiple Myeloma (MM), Acute Myeloid Leukemia (AML), and T-Cell Neoplasms (TCL). Blood, 2020, 136, 7-8.	1.4	1
366	Interstitial Lung Disease in Patients with Diffuse Large B-Cell Lymphoma Receiving CHOP-Based Chemotherapy Is Associated with the Use of Rituximab Blood, 2007, 110, 3435-3435.	1.4	1
367	Clinical Impact of TP53 Gene Mutations in Diffuse Large B-Cell Lymphoma (DLBCL): An International DLBCL Rituxan-CHOP Consortium Program Study Blood, 2009, 114, 967-967.	1.4	1
368	Prognostic Significance and Phenotypic Manifestations of MYC/BCL2 Protein Expression in Diffuse Large B-Cell Lymphoma (DLBCL) with Extranodal Organ Involvement: A Report of the International DLBCL Rituximab-CHOP Consortium Program Study. Blood, 2012, 120, 544-544.	1.4	1
369	Soluble ST2 (sST2) Is a Novel Valuable Prognostic Marker Among Patients With Immunoglobulin Light Chain (AL) Amyloidosis. Blood, 2013, 122, 3095-3095.	1.4	1
370	Long-Term (10 Years or More) Survivors Of Multiple Myeloma: A Population-Based Analysis Of The US National Cancer Data Base. Blood, 2013, 122, 760-760.	1.4	1
371	Necrobiotic Xanthogranuloma (NXG) Associated with Monoclonal Gammopathies (MG): Clinical Features and Treatment Outcomes. Blood, 2015, 126, 1830-1830.	1.4	1
372	Anaplastic Large Cell Lymphoma of the Breast: Incidence, Patterns of Care, and Outcome in the US Population. Blood, 2015, 126, 5035-5035.	1.4	1
373	Predictors of Early Relapse Following Initial Therapy for Systemic Immunoglobulin Light Chain Amyloidosis. Blood, 2016, 128, 2082-2082.	1.4	1
374	Characteristics and Outcome of Direct Antiglobulin Test-Negative Hemolytic Anemia: A Case Series. Blood, 2016, 128, 2451-2451.	1.4	1
375	Clinical Features and Outcomes of Plasmacytoma in the United States: Analysis Using the National Cancer Data Base. Blood, 2016, 128, 3249-3249.	1.4	1
376	Clinical Presentation and Outcomes of Patients with Light Chain Amyloidosis Who Have Non-Evaluable Free Light Chains at Diagnosis. Blood, 2016, 128, 3272-3272.	1.4	1
377	Practice Patterns of Re-Initiation of Therapy at Time of Relapse or Progression Post- Autologous Stem Cell Transplant (ASCT) Among Patients with AL Amyloidosis. Blood, 2016, 128, 3444-3444.	1.4	1
378	Effect of Standard Dose Versus Risk Adapted Melphalan Conditioning on Outcomes in Systemic AL Amyloidosis Patients Undergoing Frontline Autologous Stem Cell Transplant Based on Revised Mayo Stage. Blood, 2016, 128, 4627-4627.	1.4	1

#	Article	IF	CITATIONS
379	Quantification of circulating clonal plasma cells (cPCs) via multiparametric flow cytometry (MFC) to identify patients with smoldering multiple myeloma (SMM) at high risk of progression Journal of Clinical Oncology, 2016, 34, 8015-8015.	1.6	1
380	Daratumumab-based combination therapies (DCT) in heavily-pretreated patients (pts) with relapsed and/or refractory multiple myeloma (RRMM) Journal of Clinical Oncology, 2017, 35, 8038-8038.	1.6	1
381	Factors predicting organ response in light chain amyloidosis (AL) Journal of Clinical Oncology, 2017, 35, 8048-8048.	1.6	1
382	Association between hospital volume and overall survival of patients with metastatic non-small cell lung cancer Journal of Clinical Oncology, 2017, 35, 9044-9044.	1.6	1
383	Clinical Features, Natural History, and Treatment Outcome of Idiopathic Cyclic Thrombocytopenia: Systematic Analysis of 51 Cases Reported in the Literature Blood, 2004, 104, 3929-3929.	1.4	1
384	Health-Related Quality of Life (HRQoL) in Patients (Pts) with Chronic Immune Thrombocytopenic Purpura (ITP): Results from Two Placebo-Controlled Phase 3 Studies of AMG 531 Blood, 2007, 110, 1314-1314.	1.4	1
385	Health-Related Quality of Life (HRQoL) in Patients with Chronic Immune Thrombocytopenic Purpura (ITP): Interim Results from an Open-Label Study of AMG 531 Blood, 2007, 110, 1324-1324.	1.4	1
386	Cancer Complications At the Time of Multiple Myeloma Diagnosis and the Impact of Monoclonal Gammopathy of Undetermined Significance (MGUS) Follow-up: A Population-Based Study. Blood, 2012, 120, 3996-3996.	1.4	1
387	Improvement in Renal Function and Its Impact on Survival in Patients with Newly Diagnosed Multiple Myeloma. Blood, 2014, 124, 3368-3368.	1.4	1
388	Large Deletions Involving the Beta Globin Gene Complex: Genotype-Phenotype Correlation of 119 Cases. Blood, 2015, 126, 3374-3374.	1.4	1
389	Racial and ethnic disparities in the survival of adolescents and young adults (AYA) with acute myeloid leukemia (AML) Journal of Clinical Oncology, 2016, 34, 297-297.	1.6	1
390	The influence of treatment facility volume on the mortality of multiple myeloma patients Journal of Clinical Oncology, 2016, 34, 284-284.	1.6	1
391	Disparity in early mortality among racial groups with multiple myeloma in the United States: A National Cancer Data Base study of 108,352 patients Journal of Clinical Oncology, 2016, 34, 311-311.	1.6	1
392	Dexamethasone, rituximab and cyclophosphamide (DRC) in relapsed/refractory (R/R) and treatment naìve (TN) Waldenström macroglobulinemia (WM) Journal of Clinical Oncology, 2016, 34, 7552-7552.	1.6	1
393	Monoclonal Gammopathy of Undetermined Significance (MGUS) Follow-up Practice Patterns in the US: Frequency of Visits, Types of Tests and Concordance with Clinical Practice Guidelines. Blood, 2016, 128, 5906-5906.	1.4	1
394	Sex-Based Disparities in Venous Thromboembolism Sociodemographics and Outcomes: A National Inpatient Sample (NIS)-Based Analysis. Blood, 2016, 128, 5918-5918.	1.4	1
395	Natural history of t(11;14) multiple myeloma (MM) Journal of Clinical Oncology, 2017, 35, 8014-8014.	1.6	1
396	Treatment Facility Volume and Outcomes in Waldenstrom Macroglobulinemia. Blood, 2018, 132, 622-622.	1.4	1

#	Article	IF	CITATIONS
397	Confirming the Presence of a Smoldering T and B PLL Associated with Improved 5 Year OS: Using the National Cancer Data Base. Blood, 2018, 132, 5543-5543.	1.4	1
398	Development of Thrombocytopenia and Survival Outcomes in Newly Diagnosed Multiple Myeloma. Blood, 2018, 132, 1902-1902.	1.4	1
399	Tumor Mutational Burden and Other Immunotherapy Markers in Histiocytic Neoplasms Using Next Generation Sequencing. Blood, 2018, 132, 1112-1112.	1.4	1
400	Prognosis of Patients with Waldenström Macroglobulinemia: A Simplified Model. Blood, 2018, 132, 4152-4152.	1.4	1
401	Patient-Reported Outcome Driven Case Management System for Hematology — a Prospective Study. Blood, 2018, 132, 719-719.	1.4	1
402	A Novel Approach to Risk Stratification in Multiple Myeloma Using ISS Stage and FISH. Blood, 2019, 134, 1800-1800.	1.4	1
403	Clinical Outcomes and Cytogenetic Features of Primary Plasma Cell Leukemia (pPCL) in the Era of Novel Agent Induction Therapy. Blood, 2019, 134, 5490-5490.	1.4	1
404	Efficacy of Cobimetinib in Rosai-Dorfman Disease. Blood, 2021, 138, 1506-1506.	1.4	1
405	BRAF Fusions in Histiocytic Disorders: Frequency and Clinical Characteristics. Blood, 2021, 138, 2582-2582.	1.4	1
406	Determination of Relapse Risk By Complement Gene Variants after Eculizumab Discontinuation in Complement-Mediated Thrombotic Microangiopathy: A Retrospective Review. Blood, 2020, 136, 25-26.	1.4	1
407	Unmet Needs in AL Amyloidosis: Outcomes in the Modern Era Among the Highest Risk, Newly Diagnosed AL Amyloidosis Patients. Blood, 2020, 136, 31-32.	1.4	1
408	A <scp>populationâ€based</scp> study of acute panmyelosis with myelofibrosis in the United States: 2004–2015. American Journal of Hematology, 2022, 97, .	4.1	1
409	Sarcopenia identified by computed tomography (CT) imaging using a machine learning–based convolutional neural network (CNN) algorithm impacts survival in patients with newly diagnosed multiple myeloma (NDMM) Journal of Clinical Oncology, 2022, 40, 110-110.	1.6	1
410	Human cyclic thrombocytopenia and Anaplasma spp. infection. European Journal of Haematology, 2005, 74, 182-183.	2.2	0
411	Reconciling New Organ Donation Laws With Patient's Autonomy and Rights to Self-determination of End-of-Life Medical Care–Reply–II. Mayo Clinic Proceedings, 2008, 83, 506.	3.0	0
412	Proportions of bone marrow lymphocyte subsets at diagnosis may predict survival in patients with newly diagnosed diffuse large B-cell lymphoma independently of the international prognostic index. American Journal of Hematology, 2011, 86, 622-624.	4.1	0
413	Phenotypic and Genotypic Profiling of MDM2, Respective to the TP53 Genetic Status, in Diffuse Large B-cell Lymphoma Patients Treated With Rituximab-CHOP Immunochemotherapy: A Report from the International DLBCL Rituximab-CHOP Consortium Program. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, S146-S147.	0.4	0
414	Clinical and Biological significance of MYC/BCL6 dual gene rearrangements and protein co-expression in de novo diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, S228.	0.4	0

#	Article	IF	CITATIONS
415	A simple model to predict survival using age, comorbidities and functional status in patients with multiple myeloma (MM). Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, e94-e95.	0.4	0
416	The Reversal of Renal Impairment and its Impact on Survival in Newly Diagnosed Multiple Myeloma Patients. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, S239.	0.4	0
417	Pulmonary Presentation Without Concurrent Bone Involvement in Erdheim-Chester Disease: A Report of Two Cases. Chest, 2016, 150, 1090A.	0.8	0
418	61-Year-Old Man With Right Knee Pain and Chronic Anemia. Mayo Clinic Proceedings, 2016, 91, 1640-1644.	3.0	0
419	Clinical Features and Outcomes of Plasmacytoma: a National Cancer Database Study (2000 – 2011). Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, S81-S82.	0.4	0
420	The Authors Reply. Kidney International, 2017, 92, 517.	5.2	0
421	Bortezomib Versus Non-Bortezomib Based Initial Treatment for Transplant Ineligible Patients with Light Chain Amyloidosis. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, e140-e141.	0.4	0
422	LOW GRADE B-CELL NON-HODGKIN LYMPHOMAS INVOLVING THE CENTRAL NERVOUS SYSTEM: AN ANALYSIS FROM THE NATIONAL CANCER DATABASE. Hematological Oncology, 2017, 35, 224-225.	1.7	0
423	Letter to the Editor: Chicken Noodle Soup (Capsule) for the Soul?. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 108-109.	4.9	0
424	In Reply. Oncologist, 2018, 23, e163.	3.7	0
425	Evaluation of thrombocytopenia in the hematology clinic: a case series from a large tertiary care center. Blood Research, 2018, 53, 166.	1.3	0
426	43-Year-Old Man With Polyuria and Bone Pain. Mayo Clinic Proceedings, 2020, 95, e13-e18.	3.0	0
427	The Reply. American Journal of Medicine, 2021, 134, e229.	1.5	0
428	A population-based study of acute panmyelosis with myelofibrosis in the United States: 2004 to 2015 Journal of Clinical Oncology, 2021, 39, e19003-e19003.	1.6	0
429	Impact of stratifying levels of serum lactate dehydrogenase (LDH) at diagnosis on the overall survival (OS) in newly diagnosed multiple myeloma (NDMM) Journal of Clinical Oncology, 2021, 39, e20016-e20016.	1.6	0
430	Phenotypes and prognostic factors in adults with Langerhans cell histiocytosis Journal of Clinical Oncology, 2021, 39, 7049-7049.	1.6	0
431	<i>BRAF</i> ^{V600E} frequency and impact on outcomes in adults with langerhans cell histiocytosis Journal of Clinical Oncology, 2021, 39, 7050-7050.	1.6	0
432	Trends in female representation in clinical practice guidelines (CPGs) among major cancer organizations Journal of Clinical Oncology, 2021, 39, 11006-11006.	1.6	0

#	Article	IF	CITATIONS
433	Circulating Endothelial Cells (CEC) and Angiogenesis-Related Factors in Multiple Myeloma (MM) Blood, 2005, 106, 5064-5064.	1.4	0
434	Circulating Endothelial Cells and Circulating Endothelial Progenitor Cells in Polycythemia Vera Blood, 2006, 108, 4900-4900.	1.4	0
435	Association between Platelet Autoantibody Specificity and Response to Intravenous Immunoglobulin G in the Treatment of Patients with Immune Thrombocytopenia Blood, 2006, 108, 3987-3987.	1.4	0
436	Proportions of Bone Marrow Lymphocyte Subsets Predict Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma Independent of International Prognostic Index. Blood, 2008, 112, 2834-2834.	1.4	0
437	Significant Survival Disparity Between Chronic Lymphocytic Leukemia (CLL) and Stage IV Small Lymphocytic Lymphoma (SLL) Patients: Analysis Using the Surveillance, Epidemiology and End Results (SEER) Database. Blood, 2008, 112, 4171-4171.	1.4	0
438	Level of Scientific Evidence Underlying Recommendations Arising From the National Comprehensive Cancer Network Clinical Practice Guidelines for Hematologic Malignancies. Blood, 2011, 118, 509-509.	1.4	0
439	Risk of Second Cancers Among Multiple Myeloma (MM) Patients in the Era of Novel Agents: Analysis Using the Surveillance, Epidemiology and End Results (SEER) Database. Blood, 2011, 118, 1859-1859.	1.4	0
440	Utility of Routine Bone Marrow Fluorescent in Situ Hybridization (FISH) Panel Testing in Patients Suspected of Myelodysplastic Syndrome (MDS): An Analysis of 3,418 Patients and Comparison of Academic Versus Community Practices. Blood, 2012, 120, 3855-3855.	1.4	0
441	Natural History Of Smoldering Monoclonal Gammopathy-Associated Malignancies: A Population-Based Study. Blood, 2013, 122, 5318-5318.	1.4	0
442	Effect Of Immediate Prior-Line Lenalidomide Or Thalidomide Therapy On Response To Pomalidomide In Multiple Myeloma. Blood, 2013, 122, 1979-1979.	1.4	0
443	Radiation Therapy Significantly Improves Survival Of Patients With Diffuse Large B-Cell Lymphoma Associated With MYC Translocation: A Report From The International DLBCL Rituximab-CHOP Consortium Program. Blood, 2013, 122, 213-213.	1.4	0
444	NF-κB Subunit c-Rel Cooperates with Myc and Mutated p53 to Confer Significantly Worse Survival in Patients with Diffuse Large B-Cell Lymphoma: A Report from the International DLBCL Rituximab-CHOP Consortium Program. Blood, 2014, 124, 1620-1620.	1.4	0
445	Pomalidomide Plus Low-Dose Dexamethasone (Pom/Dex) in Relapsed Lenalidomide Refractory Myeloma: Long Term Follow up and Comparison of 2 Mg Vs 4 Mg Doses. Blood, 2014, 124, 4780-4780.	1.4	0
446	Impact of Beta Blocker on Clinical Outcomes of Multiple Myeloma (MM) Patients. Blood, 2014, 124, 4751-4751.	1.4	0
447	Enteropathy-Associated T-Cell Lymphoma in the U.S.: A Population-Based Study Using Surveillance, Epidemiology, and End Results Program and National Cancer Data Base. Blood, 2014, 124, 1631-1631.	1.4	0
448	Outcomes and treatment of patients with POEMS syndrome experiencing progression or relapse after first line treatment Journal of Clinical Oncology, 2015, 33, 8594-8594.	1.6	0
449	Early high-dose therapy and autologous stem-cell transplantation in angioimmunoblastic T-cell lymphoma: Outcome study using the National Cancer Data Base Journal of Clinical Oncology, 2015, 33, 8560-8560.	1.6	0
450	Clinical outcomes in t(11;14) multiple myeloma Journal of Clinical Oncology, 2015, 33, 8592-8592.	1.6	0

#	Article	IF	CITATIONS
451	Survival trends in young patients with Waldenstrom macroglobulinemia (WM) Journal of Clinical Oncology, 2015, 33, 8596-8596.	1.6	0
452	Estimating the Annual Volume of Hematologic Cancer Cases per Hematologist-Oncologist in the United States: Are We Treating Rare Cancers Too Rarely?. Blood, 2015, 126, 3297-3297.	1.4	0
453	A Population-Based Study of Large Granular Lymphocyte Leukemia: Analysis of 978 Patients Using the SEER and NCDB Databases. Blood, 2015, 126, 3302-3302.	1.4	0
454	Impact of the Type of Treatment Facility on the Outcome of Acute Myeloid Leukemia in the Adolescents and Young Adults: A National Cancer Data Base (NCDB) Study from 2003-2011. Blood, 2015, 126, 529-529.	1.4	0
455	N-Terminal Fragment of the Type-B Natriuretic Peptide (NT-proBNP) Is a Prognostic Factor for Overall Survival in Newly Diagnosed Patients with Multiple Myeloma (MM). Blood, 2015, 126, 3292-3292.	1.4	0
456	The Influence of Treatment Facility Volume on Survival of Non-Hodgkin Lymphoma: Determining the Volume-Outcome Relationship. Blood, 2015, 126, 266-266.	1.4	0
457	AL Amyloidosis and Patient Reported Quality of Life. Blood, 2015, 126, 3317-3317.	1.4	0
458	Disparity in the Overall Survival Improvement over Time and the Effect Time-to-Treatment on the Outcome of Acute Promyelocytic Leukemia: A US National Cancer Data Base Study from 1998-2011. Blood, 2015, 126, 3747-3747.	1.4	0
459	Occurrence and Prognostic Significance of Cytogenetic Evolution in Patients with Multiple Myeloma. Blood, 2015, 126, 4176-4176.	1.4	0
460	Natural History of Amyloidosis Isolated to Fat and Bone Marrow Aspirate. Blood, 2015, 126, 5303-5303.	1.4	0
461	Incidence and Outcomes of Neutropenia in Patients with Celiac Disease- a Consecutive Analysis of 1729 Patients. Blood, 2015, 126, 1013-1013.	1.4	0
462	In-hospital outcomes of tumor lysis syndrome: A population-based study using the National Inpatient Sample (NIS) Journal of Clinical Oncology, 2016, 34, 6582-6582.	1.6	0
463	Changes in serum alkaline phosphatase levels to predict response to ixazomib-based therapy in patients with newly diagnosed multiple myeloma Journal of Clinical Oncology, 2016, 34, 8053-8053.	1.6	0
464	Clinical utility of the revised international staging system (RISS) in newly diagnosed multiple myeloma Journal of Clinical Oncology, 2016, 34, 8017-8017.	1.6	0
465	Treatment trends and outcomes in early-stage Hodgkin lymphoma in elderly: A National Cancer Data Base analysis Journal of Clinical Oncology, 2016, 34, 7536-7536.	1.6	0
466	Immunoparesis in newly diagnosed AL amyloidosis as a marker for response and survival Journal of Clinical Oncology, 2016, 34, 8016-8016.	1.6	0
467	Desiderosmia (Craving of Olfaction): A Novel Symptom Associated with Iron Deficiency Anemia. Blood, 2016, 128, 4827-4827.	1.4	0
468	In-Hospital Outcomes of Neutropenic Fever: A Study Using the National Inpatient Sample, Years 2009-2013. Blood, 2016, 128, 4762-4762.	1.4	0

#	Article	IF	CITATIONS
469	Significant Variability in the Initial Workup of Thrombocytopenia in the Hematology Clinic - What Is the "Optimal" Workup?. Blood, 2016, 128, 5966-5966.	1.4	0
470	Prognostic Implications of Multiple Cytogenetic High-Risk Abnormalities in Patients with Newly Diagnosed Multiple Myeloma. Blood, 2016, 128, 5615-5615.	1.4	0
471	Thyroid Functional Abnormalities in Newly Diagnosed AL Amyloidosis: Frequency and Influence By Type of Organ Involvement and Disease Burden. Blood, 2016, 128, 3273-3273.	1.4	0
472	Changes in Uninvolved Immunoglobulins during Multiple Myeloma Therapy. Blood, 2016, 128, 3251-3251.	1.4	0
473	Survival Trends in Young Patients with Waldenstrom Macroglobulinemia: Over 5 Decades of Experience. Blood, 2016, 128, 1810-1810.	1.4	0
474	Beta-Blockers Improved Survival Outcomes in Patients with Multiple Myeloma: A Retrospective Evaluation. Blood, 2016, 128, 3306-3306.	1.4	0
475	The Prognostic Significance of Polyclonal Bone Marrow Plasma Cells in Patients with Actively Relapsing Multiple Myeloma. Blood, 2016, 128, 1194-1194.	1.4	0
476	Fluorescence in-Situ Hybridization (FISH) Analysis in Untreated AL Amyloidosis Has an Independent Prognostic Impact By Abnormality Type and Treatment Category. Blood, 2016, 128, 3269-3269.	1.4	0
477	Disparities in the Upfront Use of Hematopoietic Stem Cell Transplant Among Patients with Acute Myeloid Leukemia. Blood, 2016, 128, 3543-3543.	1.4	0
478	Treatment Patterns and Outcomes Following Initial Relapse in Patients with Relapsed Systemic Immunoglobulin Light Chain Amyloidosis. Blood, 2016, 128, 3338-3338.	1.4	0
479	Predicting Poor Overall Survival in Patients with Newly Diagnosed Multiple Myeloma and Standard-Risk Cytogenetics Treated with Novel Agents. Blood, 2016, 128, 3255-3255.	1.4	0
480	Characterizing the Use of Gastrointestinal Procedures in the Workup of Anemia: Patterns of Care and Areas for Improvement. Blood, 2016, 128, 4748-4748.	1.4	0
481	Impact of Melphalan-Based Chemotherapy on Stem Cell Collection in Patients with Light Chain Amyloidosis. Blood, 2016, 128, 2187-2187.	1.4	0
482	The use of proteasome inhibitors among patients with POEMS syndrome Journal of Clinical Oncology, 2017, 35, e19530-e19530.	1.6	0
483	Outcomes according to involved free light chain (FLC) levels in patients with normal FLC ratio after initial therapy in light chain amyloidosis (AL) Journal of Clinical Oncology, 2017, 35, 8049-8049.	1.6	0
484	Risk stratification by detection of clonal circulating plasma cells (CPCs) by multi-parametric flow cytometry (MFC) in light chain amyloidosis (AL) Journal of Clinical Oncology, 2017, 35, 8047-8047.	1.6	0
485	Overuse of organ biopsies in immunoglobulin light chain (AL) amyloidosis: The consequence of failure of early recognition Journal of Clinical Oncology, 2017, 35, e19532-e19532.	1.6	0
486	Smoldering Waldenström's macroglobulinemia (SWM): Analysis from the National Cancer Database (NCDB) Journal of Clinical Oncology, 2017, 35, 1573-1573.	1.6	0

#	Article	IF	CITATIONS
487	In-hospital outcomes of acute myeloid leukemia (AML) patients undergoing allogeneic hematopoietic stem cell transplant (HCT) Journal of Clinical Oncology, 2017, 35, e18091-e18091.	1.6	0
488	The impact of body mass index on the risk of early progression of smoldering multiple myeloma to symptomatic myeloma Journal of Clinical Oncology, 2017, 35, 8032-8032.	1.6	0
489	Clinical and Serological Characteristics of Cold Autoimmune Hemolytic Anemia with Concomitant Cold Agglutinin and Donath-Landsteiner Antibodies. Blood, 2017, 130, 927-927.	1.4	0
490	Prognostic Value of Clone Size in Paroxysmal Nocturnal Hemoglobinuria (PNH) for Thrombotic Events in Untreated Patients in the International PNH Registry. Blood, 2018, 132, 1038-1038.	1.4	0
491	Long-Term Survivorship with Active Multiple Myeloma. Blood, 2018, 132, 1912-1912.	1.4	0
492	Comparative Analysis of Staging Systems in AL Amyloidosis. Blood, 2018, 132, 3228-3228.	1.4	0
493	Early Prediction of Treatment Response in Newly Diagnosed Multiple Myeloma. Blood, 2018, 132, 3159-3159.	1.4	0
494	Comparison of Different Techniques to Identify Cardiac Involvement in Immunoglobulin Light Chain Amyloidosis. Blood, 2018, 132, 3182-3182.	1.4	0
495	Prognostic Significance of Early Immune Reconstitution in Newly Diagnosed Multiple Myeloma. Blood, 2018, 132, 3158-3158.	1.4	0
496	Impact of Acquired Del(17p) in Patients with Multiple Myeloma. Blood, 2018, 132, 4449-4449.	1.4	0
497	Long-Term AL Amyloidosis Survivors Among Non-Selected Referral Population. Blood, 2018, 132, 3226-3226.	1.4	0
498	Expected Survival in Patients with Smoldering Multiple Myeloma and Multiple Myeloma. Blood, 2018, 132, 4497-4497.	1.4	0
499	Mass Spectrometry to Measure Response in Immunoglobulin Light Chain Amyloidosis (AL). Blood, 2018, 132, 4502-4502.	1.4	0
500	Prognostic Restaging at the Time of 2nd-Line Therapy in Patients with AL Amyloidosis. Blood, 2018, 132, 5594-5594.	1.4	0
501	Optimizing Deep Response Assessment for AL Amyloidosis Using Involved Free Light Chain Level at End of Therapy. Blood, 2018, 132, 3227-3227.	1.4	0
502	Characterization of Exceptional Responders to Autologous Stem Cell Transplantation in Multiple Myeloma. Blood, 2018, 132, 4615-4615.	1.4	0
503	Frequency of Acquired Genetic Mutations and Their Prognostic Impact on Patients with Incidental Finding of Isolated 20q- in Bone Marrow without Morphologic Evidence of a Myeloid Neoplasm. Blood, 2018, 132, 4382-4382.	1.4	0
504	Incidence, Clinical Features, and Outcomes of Langerhans Cell Sarcoma in the United States. Blood, 2018, 132, 3031-3031.	1.4	0

#	Article	IF	CITATIONS
505	Association between Treatment Facility Volume and Mortality of Patients with Hodgkin Lymphoma. Blood, 2018, 132, 2257-2257.	1.4	0
506	Monoclonal Gammopathy of Undetermined Significance (MGUS): Indications for Pre-Diagnostic Testing, Subsequent Diagnoses, and Follow-up Practice. Blood, 2018, 132, 2224-2224.	1.4	0
507	PS1397 OUTCOMES OF LONGâ€TERM SURVIVORS WITH ACTIVE MULTIPLE MYELOMA. HemaSphere, 2019, 3, 64	12.7	0
508	Hypovitaminosis D Is Prevalent in Patients with Renal AL Amyloidosis and Associated with Non-t(11;14). Blood, 2019, 134, 5523-5523.	1.4	0
509	Waldenström Macroglobulinemia with Excess Plasma Cells: Is It a Distinct Entity?. Blood, 2019, 134, 1532-1532.	1.4	0
510	Metaphase Cytogenetics for Risk Stratification in Newly Diagnosed Multiple Myeloma. Blood, 2019, 134, 4396-4396.	1.4	0
511	Impact of sFLC Ratio on Outcome in Patients with MM: Validating the Utility of sFLC in Response Definition. Blood, 2019, 134, 3080-3080.	1.4	0
512	Determinants of Clinical Trial Participation and Impact on Survival Outcomes Among Patients with Newly Diagnosed Multiple Myeloma. Blood, 2019, 134, 5833-5833.	1.4	0
513	Phase 2 Trial of Ixazomib, Cyclophosphamide and Dexamethasone in Relapsed Multiple Myeloma. Blood, 2019, 134, 1904-1904.	1.4	0
514	Increased Mean Corpuscular Volume Is an Independent Predictor for Worse Overall Survival in Patients with Newly Diagnosed Light Chain Amyloidosis. Blood, 2019, 134, 5532-5532.	1.4	0
515	Sex Differences in Faculty Rank and Leadership Positions Amongst Hematologists and Oncologists in United States: A Cross-Sectional Study. Blood, 2019, 134, 3399-3399.	1.4	0
516	Desideromastica: Tactile Chew Cravings in Iron Deficiency Anemia. Blood, 2019, 134, 4815-4815.	1.4	0
517	The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients with Newly Diagnosed Multiple Myeloma. Blood, 2019, 134, 2197-2197.	1.4	0
518	An Analysis of Virus Amplification and Antitumor Responses in T-Cell Lymphoma Patients Treated with Voyager-V1 (VSV-IFNβ-NIS). Blood, 2021, 138, 1333-1333.	1.4	0
519	Prognostic Role of IL-6 in POEMS Syndrome. Blood, 2021, 138, 2700-2700.	1.4	0
520	Impact of Achieving an Early Complete Response in Multiple Myeloma and Predictors of Subsequent Outcome. Blood, 2021, 138, 3773-3773.	1.4	0
521	The Sustainability of Price Dynamics in Precision Hematology. Blood, 2021, 138, 114-114.	1.4	0
522	Classical and Non-Classical Phenotypes of Erdheim-Chester Disease: Correlating Clinical, Radiographic, and Genotypic Findings. Blood, 2021, 138, 2566-2566.	1.4	0

#	Article	IF	CITATIONS
523	Histopathologic Characterization of Vexas Syndrome. Blood, 2021, 138, 4656-4656.	1.4	Ο
524	Tumor Mutational Burden in Histiocytic Neoplasms. Blood, 2021, 138, 3634-3634.	1.4	0
525	Comparison of Conventional Xrays with CT Based Approaches for Detection of Lytic Lesions in Multiple Myeloma. Blood, 2020, 136, 27-28.	1.4	0
526	The Prognostic Significance of Acquired 1q22 Gain in Multiple Myeloma. Blood, 2020, 136, 9-10.	1.4	0
527	Detection of Monoclonal Immunoglobulin By Mass Spectrometry in Patients Evaluated for Thrombotic Microangiopathy (TMA). Blood, 2020, 136, 17-17.	1.4	О
528	A Population-Based Study of Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofibrosis in the United States from 2001-2015. Blood, 2020, 136, 48-48.	1.4	0
529	The Role of Staging Evaluation at Initial Diagnosis of Adult Patients with Clinically Isolated Pulmonary Langerhans Cell Histiocytosis. Blood, 2020, 136, 45-45.	1.4	Ο
530	A Cross Sectional Evaluation of Light Chain N-Glycosylation By MASS-FIX in Plasma Cell Disorders. Blood, 2020, 136, 44-45.	1.4	0
531	Prognostic Impact of PET Findings Post-Transplant in Multiple Myeloma. Blood, 2020, 136, 15-16.	1.4	0
532	Level of Scientific Evidence Underlying Recommendations from the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for Hematologic Malignancies: Are We Moving Forward?. Blood, 2020, 136, 32-32.	1.4	0
533	Treatments and Outcomes of Newly Diagnosed Multiple Myeloma Patients > 75 Years Old: A Retrospective Analysis. Blood, 2020, 136, 14-15.	1.4	Ο
534	Prognostic Restaging after Treatment Initiation in Patients with AL Amyloidosis. Blood, 2020, 136, 6-7.	1.4	0
535	A 3-Question Symptom Assessment Score Can Predict Outcomes in Newly Diagnosed Multiple Myeloma (MM). Blood, 2020, 136, 21-22.	1.4	0
536	A Population-Based Study of Chronic Myelomonocytic Leukemia in the United States from 2004-2015. Blood, 2020, 136, 30-31.	1.4	0
537	Female Representation in Clinical Practice Guideline Panels in 2 Major Cancer Organizations. Oncology, 2022, 36, 59-63.	0.5	0
538	Multimodality imaging of cardiac involvement in Erdheim–Chester disease. European Heart Journal Cardiovascular Imaging, 2022, , .	1.2	0
539	Impact of high-dose melphalan followed by autologous stem cell transplant in producing MRD negative complete response in newly diagnosed multiple myeloma Journal of Clinical Oncology, 2022, 40, e20001-e20001.	1.6	0
540	Insurance-based disparities in Waldenstrom Macroglobulinemia: An NCDB analysis Journal of Clinical Oncology, 2022, 40, e19562-e19562.	1.6	0

#	Article	IF	CITATIONS
541	Medicare expenditures for discarded oncology therapies Journal of Clinical Oncology, 2022, 40, 6552-6552.	1.6	0